NCT01623518View on ClinicalTrials.gov

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

ChAdOx1-NP+M1

"Dose escalation in a 3+3 study plan;~5 x10\^8 vp, 5 x10\^9 vp, 2.5 x10\^10 vp, 5 x10\^10 vp"

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01623518 - A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1 | Biotech Hunter | Biotech Hunter